A director at Ackermans & Van Haaren sold 1,000 shares at 278.300EUR and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Syensqo - Participation notification by BlackRock Inc. Communiqué de pressePersbericht Regulated Participation notifications by BlackRock Inc. Brussels, Belgium – April 24, 2026 - 8:45 CESTAccording to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (12 Throgmorton Avenue, London EC2N 2DL, UK) recently sent Syensqo the following transparency notification indicating that it crossed the threshold of 3%. Here is the summary of the move: Date on which the threshold was crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotal...
Pharvaris presented data evaluating safety margins of combining deucrictibant immediate-release (IR) with deucrictibant extended-release (XR) tablet at the Consortium of Independent Immunology Clinics (CIIC) conference, held 17-19 April. The results demonstrated that combined use of a 40 mg deucrictibant XR tablet for prophylaxis and 1 or 2 deucrictibant IR 20 mg capsule(s) in the event of a breakthrough attack, while on prophylaxis, is supported by evidence of adequate safety margins. This buil...
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), presented data evaluating safety margins of administration of deucrictibant immediate-release (IR) capsule(s) in combination with ...
Pharvaris reported FY25 results with a cash position of € 292m (YE24: € 281m) and reiterated its pipeline timelines. We most look forward to topline data from the phase 3 (CHAPTER-3) trial of deucrictibant in HAE prophylaxis in 3Q26, and we're confident going into this readout given the de-risked MOA and strong phase 2 dataset. We expect an attack reduction rate in line with injectable therapies, thereby positioning deucrictibant as the only candidate to offer both oral convenience and high effi...
Convening Notice to Syensqo Ordinary Shareholders’ Meeting Regulated Convening Notice to Syensqo Ordinary Shareholders’ Meeting Brussels, Belgium – April 3, 2026 - 08:30 CEST Syensqo announces that it has published today the convening notice to its Ordinary Shareholders’ Meeting, which will be held on Tuesday, May 5, 2026 at SQUARE Brussels, Mont des Arts, 1000 Brussels, at 10.30 a.m. CEST. All documents relating to the Shareholders’ Meeting are available on Syensqo’s website. Shareholders will be asked to vote on a number of resolutions, including the approval of Syensqo’s financial s...
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacksCash and cash equivalents of €292 million as of December 31, 2025 ZUG, Switzerland, April 02, 2...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.